Nizatidine, a new H2-receptor antagonist for treatment of duodenal ulcer disease, was evaluated in a unique two-phase, placebo-controlled, randomized, double-blind, multicenter clinical trial. Patients received either 150 mg nizatidine twice daily or placebo for 4 weeks (phase I). If ulcer healing did not occur during phase I, patients were randomly reallocated to receive either 150 mg nizatidine twice daily or placebo for an additional 4 weeks (phase II). Patients with a healed ulcer continued on the same therapy. All patients were endoscoped at week 8. Healing rates at week 2 were 93 of 265 (35%) nizatidine-treated patients and 55 of 260 (21%) placebo-treated patients (p less than 0.001); at week 4, healing rates were 198 of 259 (76%) nizatidine-treated patients and 95 of 243 (39%) placebo-treated patients (p less than 0.001). In phase II, ulcer healing occurred in 46 of 86 (53%) nizatidine-treated patients and in 23 of 90 (26%) placebo-treated patients (p = 0.002). In patients who had a healed ulcer at previous endoscopies, 18 of 178 (10%) nizatidine-treated patients and 10 of 81 (12%) placebo-treated patients had a recurrence of duodenal ulcer. Smokers who had histories of previous ulcers were more likely to have an early recurrence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/clpt.1989.144 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of pantoprazole in older patients with erosive esophagitis.
Dis Esophagus
January 2008
Department of Medicine, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA.
Several studies suggest that older adults with gastroesophageal reflux disease (GERD) are more likely to develop complications, including erosive esophagitis, but it is unclear whether erosive esophagitis is more difficult to treat in older patients. The purpose of this study was to determine if adults > or = 65 years with erosive esophagitis are more difficult to treat than younger adults. The study was a post hoc analysis of two double-blind, randomized, multicenter trials of patients with erosive esophagitis.
View Article and Find Full Text PDFComparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study.
Aliment Pharmacol Ther
December 2002
CURE/VAGLAHS, Los Angeles, CA, USA.
Background: Pantoprazole is a proton pump inhibitor approved for the treatment of erosive oesophagitis and gastro-oesophageal reflux disease.
Aim: To compare the efficacy and safety of pantoprazole vs. nizatidine for the treatment of symptomatic gastro-oesophageal reflux disease and endoscopically documented erosive oesophagitis (grade > or = 2).
Risk factors of relapse in gastric ulcer: a one-year, double-blind, comparative study of nizatidine versus placebo.
Ital J Gastroenterol
August 1994
Servizio di Gastroenterologia ed Endoscopia Digestiva, OO.CC.RR. Venezia, Italy.
A controlled, double-blind study with nizatidine in gastric ulcer maintenance treatment was recently performed. Univariate analysis of results after 12 months showed that: a) younger patients have a poor outcome (among nizatidine-treated); b) smoking is a risk factor for relapse; c) ulcers of the lesser curvature of the corpus relapsed more frequently than the others. The present work is a more in-depth analysis of the results using the stepwise logistic regression.
View Article and Find Full Text PDFNizatidine as maintenance treatment of duodenal ulcer. Clinical results.
Scand J Gastroenterol Suppl
March 1995
Groupe de Biochimie et de Physiopathologie Digestive et Nutritionnelle, Hôpital Charles Nicolle, Rouen, France.
In assessing treatments for chronic diseases such as duodenal ulcer (DU), measuring the patient's quality of life (QoL) is as important as objective measures of treatment efficacy. This study was part of a larger study assessing the QoL of patients with DU treated with nizatidine. The aim of this part of the 12-month study was to assess the clinical efficacy and the influence of maintenance therapy with nizatidine on the long-term treatment of patients with healed DU.
View Article and Find Full Text PDFPeptic ulcer in the elderly--a double-blind, short-term study comparing nizatidine 300 mg with ranitidine 300 mg. GISU (Interdisciplinary Ulcer Study Group).
Aliment Pharmacol Ther
December 1993
Servizio di Gastroenterologia ed Endoscopia Digestiva, Venezia, Italy.
Unlabelled: This was a randomized, double-blind, multicentre, short-term study comparing ranitidine and nizatidine at the standard dosages of 300 mg at bedtime. In 49 centres in Italy, all peptic ulcer patients aged over 65 years and with endoscopically documented acute disease were considered eligible for the study. Clinical check-ups were repeated every 3 weeks, while the endoscopic and biochemical assessments were scheduled at 6 and (in unhealed patients) 12 weeks.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!